ArticleScientific reports2017
Plasma GDF15 level is elevated in psychosis and inversely correlated with severity.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Transdiagnostic determinants of Growth Differentiation Factor-15 (GDF-15) in psychiatric in-patients: age, renal indices, interleukin-6 (IL-6) and soluble urokinase plasminogen activator receptor (suPAR).Brain, behavior, & immunity - health · 2026Article
- Reductive Stress and Dysregulated Energy Metabolism in Schizophrenia: Mechanisms and Therapeutic Targets.Biological psychiatry · 2026Review
- Psychosis as a multisystem disorder of aberrant aging.npj aging · 2026Review
- Mechanistic insights into the liver-brain axis during chronic liver disease.Nature reviews. Gastroenterology & hepatology · 2026Review
- Serum GDF-15 Levels in Pediatric ADHD: Associations with Symptom Severity and Stimulant Exposure.Neuropsychiatric disease and treatment · 2026Article
- Biopsychosocial correlates of resting and stress-reactive salivary GDF15: preliminary findings.Brain, behavior, and immunity · 2025Article
- Increased GDF-15 in chronic male patients with schizophrenia: correlation with body mass index and cognitive impairment.Schizophrenia (Heidelberg, Germany) · 2024Article
- COVID-19 in People With Schizophrenia: Potential Mechanisms Linking Schizophrenia to Poor Prognosis.Frontiers in psychiatry · 2021Article
- Article
- Schizophrenia and Epigenetic Aging Biomarkers: Increased Mortality, Reduced Cancer Risk, and Unique Clozapine Effects.Biological psychiatry · 2020Article
- Mitochondrial DNA copy number is associated with psychosis severity and anti-psychotic treatment.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accumulating evidence suggests that GDF15 is a biomarker for ageing and morbidity of many somatic disorders such as cancer and inflammatory disorders. Recently, elevated serum GDF15 level was proposed as a marker for mood disorder. However, psychosis severity was not investigated in relation to plasma GDF15 levels. In the present study we measured GDF15 levels in plasma of 120 psychosis patients compared to 120 age and gender matched healthy controls. Within the patient cohort GDF15 levels were evaluated for association with age, gender, lifestyle factors, C-reactive protein levels, psychosis severity and metabolic disorder. Psychosis patients had elevated GDF15 levels compared to controls (median
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.